Thalidomide-O-amido-C4-NH2 TFA

Cat. No.: HY-103613

CAS No.: 1799711-25-3

Molecular Formula: $C_{21}H_{23}F_3N_4O_8$

Molecular Weight: 516.42

Target: E3 Ligase Ligand-Linker Conjugates

Pathway: PROTAC

Storage: 4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 42.86 mg/mL (82.99 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	1.9364 mL	9.6820 mL	19.3641 mL
	5 mM	0.3873 mL	1.9364 mL	3.8728 mL
	10 mM	0.1936 mL	0.9682 mL	1.9364 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (4.84 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (4.84 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (4.84 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Thalidomide-O-amido-C4-NH2 TFA (Cereblon Ligand-Linker Conjugates 6 TFA) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

IC_{50} & Target

Cereblon

REFERENCES

[1]. Zhou B, et al. Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins withPicomolar Cellular Potencies and Capable of Achieving

Tumor Regression. J Med Chem. 2017 Mar 24.

[2]. James Bradner, et al. Methods to induce targeted protein degradation through bifunctional molecules. WO 2017024317 A2.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA